Will Neuralstem Phase II Results Pave The Road To A Stem Cell Cure For ALS?

NSI-566 Phase I data, along with management hints and patient blogs would seem to suggest that the Phase II study will meet its endpoints successfully. With its low market cap, high cash position and low burn rate, Neuralstem looks like an attractive investment at this point.

http://ift.tt/1LdGiHM